AOD-9604 5MG
$29.00
AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of the human growth hormone sequence, with an added tyrosine residue at the N-terminus. It reproduces the C-terminal fragment of hGH and does not contain the regions required for growth hormone receptor binding.
Because it lacks those regions, researchers use it to isolate fragment-specific activity from broader somatotropic signaling in comparative models.
Researchers study AOD-9604 in:
- Lipolysis and lipogenesis assays in adipocyte culture
- Structure-activity studies of hGH fragments
- Comparative studies against the full-length hGH sequence
- Chondrocyte and cartilage matrix models
- Peptide stability and formulation research
For research use only. Not for human or veterinary use.
MECHANISM
How Does It Work?
AOD-9604 works through pathways involved in fat metabolism, specifically fat breakdown and reduced fat storage.
| Lipolysis — Fat Breakdown | Lipogenesis Inhibition — Stops Fat Storage |
|---|---|
| AOD-9604 activates beta-3 adrenergic receptors on fat cells, signaling them to release stored fatty acids into the bloodstream to be used as fuel. | At the same time, AOD-9604 inhibits lipogenesis — the process by which the body converts excess calories into stored fat. |
| No IGF-1 Elevation | No Effect on Blood Sugar |
|---|---|
| Unlike full growth hormone therapy, AOD-9604 does not significantly raise IGF-1 levels according to clinical research. | Clinical studies showed no significant changes in blood glucose or insulin sensitivity at standard research concentrations. |
| Cartilage & Joint Research | No Water Retention |
|---|---|
| Emerging studies are exploring possible cartilage repair and joint inflammation support applications. | Research suggests AOD-9604 does not activate pathways associated with water retention seen in full GH therapy. |
Researchers distinguish AOD-9604 from other metabolic peptides because it works directly on fat cells without suppressing appetite or broadly affecting hormonal systems.
PHYSICAL PROPERTIES
| Property | Details |
|---|---|
| Classification | Human Growth Hormone fragment — amino acids 177-191 |
| Amino Acids | 15 amino acids |
| Molecular Weight | 1,817.1 g/mol |
| Form | White lyophilized powder |
| Solubility | Water-soluble |
| Purity | 98%+ (HPLC verified) |
| Administration | Subcutaneous injection |
| Storage | Refrigerated 36-46°F (2-8°C). Protect from light. Avoid freeze-thaw cycles. |
| Stability | 24 months lyophilized. Use within 30 days once reconstituted. |
POTENTIAL SIDE EFFECTS IN RESEARCH
AOD-9604 has demonstrated a strong safety profile in documented clinical research, with no serious adverse events attributed directly to the peptide.
| Injection Site Irritation | Mild Headache |
|---|---|
| Mild redness or discomfort at the injection site. Typically resolves quickly without intervention. | Occasionally reported, especially early in research protocols. Generally mild and short-lived. |
| Mild Dizziness | Mild Nausea |
|---|---|
| Temporary lightheadedness has been reported in some research subjects, usually early in protocols. | Rare and transient compared to GLP-1 compounds. |
| Fatigue | No IGF-1 or Glucose Disruption |
|---|---|
| Mild temporary fatigue has occasionally been reported in research observations. | Clinical trials consistently showed no meaningful IGF-1 elevation or significant blood glucose disruption. |
Compared with full GH therapy and some other fat-loss compounds, AOD-9604 research indicates a milder side effect profile with no documented water retention or significant glucose disruption.
DISCLAIMER
This product is exclusively for laboratory research. Not approved for human or veterinary use.
All products sold by Ikon Peptides are intended exclusively for in-vitro laboratory research. Not approved for human consumption or veterinary use. These statements have not been evaluated by the FDA.
MAECENAS IACULIS
Vestibulum curae torquent diam diam commodo parturient penatibus nunc dui adipiscing convallis bulum parturient suspendisse parturient a.Parturient in parturient scelerisque nibh lectus quam a natoque adipiscing a vestibulum hendrerit et pharetra fames nunc natoque dui.
ADIPISCING CONVALLIS BULUM
- Vestibulum penatibus nunc dui adipiscing convallis bulum parturient suspendisse.
- Abitur parturient praesent lectus quam a natoque adipiscing a vestibulum hendre.
- Diam parturient dictumst parturient scelerisque nibh lectus.
Scelerisque adipiscing bibendum sem vestibulum et in a a a purus lectus faucibus lobortis tincidunt purus lectus nisl class eros.Condimentum a et ullamcorper dictumst mus et tristique elementum nam inceptos hac parturient scelerisque vestibulum amet elit ut volutpat.
Related products
